What question did this study set out to answer?

Provide rapid, evidence-based updates to clinical practice recommendations regarding the use of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer management.

September 23, 2022Journal of Clinical Oncology

Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update

View Full Paper

Ask AI

Bookmark

Authors

WTWilliam P. TewMemorial Sloan Kettering Cancer Center CLChristina LacchettiAmerican Society of Clinical Oncology EKElise C. KohnNational Institutes of Health

Discussion

Member takes

Implication

Clinical practice guideline update reports revised PARP inhibitor recommendations for ovarian cancer management, highlighting rapid integration of practice-changing evidence into patient care.

Key Points

Provide rapid, evidence-based updates to clinical practice recommendations regarding the use of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer management.
Conducted an evidence review following the standardized methodology detailed in the ASCO Guideline Methodology Manual to identify practice-changing data.
Updated clinical recommendations in response to newly available trial data regarding PARP inhibitor therapy in ovarian cancer.
Established timely guidance to help clinicians and patients choose the most effective and up-to-date evidence-based cancer treatments.

Cite This Study

Tew et al. (2022) studied this question.

synapsesocial.com/papers/6a7c93d7f501f50849cf7ef9 https://doi.org/10.1200/jco.22.01934

View Full Paper

Ask AI

Bookmark

Implication

Clinical practice guideline update reports revised PARP inhibitor recommendations for ovarian cancer management, highlighting rapid integration of practice-changing evidence into patient care.